Literature DB >> 18490414

Pathogenesis of cutaneous lupus erythematosus.

A Kuhn1, M Bijl.   

Abstract

Although for decades sunlight was suspected to be involved in the development of cutaneous lupus erythematosus (CLE), only in recent years research on the effects of ultraviolet irradiation on the skin of patients with CLE has resulted in a more comprehensive model for the pathogenesis of the disease. In this model, exposure to UV light induces apoptosis of keratinocytes and the release of pro-inflammatory cytokines. In susceptible patients, the presence or even accumulation of apoptotic cells results in the induction of characteristic inflammatory skin lesions, which might be due to a delayed and pro-inflammatory clearance of these apoptotic cells. Many other factors, in part genetically determined, are involved in CLE resulting in a very heterogeneous clinical manifestation. Among these factors, presence of autoantibodies, a decreased number of regulatory T cells at the site of inflammation and increased expression of pro-inflammatory cytokines like TNFalpha and IFN-inducible protein myxovirus protein A have been shown to play a role in the pathogenesis of CLE.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18490414     DOI: 10.1177/0961203308090019

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  9 in total

1.  Lupus serum IgG induces skin inflammation through the TNFR1 signaling pathway.

Authors:  Guo-Min Deng; Lena Liu; Vasileios C Kyttaris; George C Tsokos
Journal:  J Immunol       Date:  2010-05-14       Impact factor: 5.422

2.  Cutaneous Connective Tissue Diseases: Epidemiology, Diagnosis, and Treatment.

Authors:  Bobby Y Reddy; Basil M Hantash
Journal:  Open Dermatol J       Date:  2009-01-01

3.  Filgotinib or lanraplenib in moderate to severe cutaneous lupus erythematosus: a phase 2, randomized, double-blind, placebo-controlled study.

Authors:  Victoria P Werth; Roy Fleischmann; Michael Robern; Zahi Touma; Iyabode Tiamiyu; Oksana Gurtovaya; Alena Pechonkina; Afsaneh Mozaffarian; Bryan Downie; Franziska Matzkies; Daniel Wallace
Journal:  Rheumatology (Oxford)       Date:  2022-05-30       Impact factor: 7.046

Review 4.  Why can't we find a new treatment for SLE?

Authors:  Robert Eisenberg
Journal:  J Autoimmun       Date:  2009-03-28       Impact factor: 7.094

Review 5.  Recent developments in the role of high-mobility group box 1 in systemic lupus erythematosus.

Authors:  Fleur Schaper; Johanna Westra; Marc Bijl
Journal:  Mol Med       Date:  2014-03-13       Impact factor: 6.354

6.  Update on the use of topical calcineurin inhibitors in cutaneous lupus erythematosus.

Authors:  Michael Sticherling
Journal:  Biologics       Date:  2011-02-14

Review 7.  Cutaneous lupus erythematosus: An update.

Authors:  Carina M Grönhagen; Filippa Nyberg
Journal:  Indian Dermatol Online J       Date:  2014-01

8.  Copy Number Variation of TLR-7 Gene and its Association with the Development of Systemic Lupus Erythematosus in Female Patients from Yucatan Mexico.

Authors:  Guillermo Valencia Pacheco; Darig Cámara Cruz; Lizbeth J González Herrera; Gerardo J Pérez Mendoza; Guadalupe I Adrián Amaro; Yumi E Nakazawa Ueji; Angélica V Angulo Ramírez
Journal:  Genet Epigenet       Date:  2014-07-22

9.  A case of subacute cutaneous lupus erythematosus as a result of ranibizumab (Lucentis) treatment.

Authors:  Marko Andric; Shreya Dixit; Dana Robaei; Rosemary Watchorn; Nitin Verma
Journal:  Indian J Ophthalmol       Date:  2013-12       Impact factor: 1.848

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.